Published in Mol Ther Methods Clin Dev on May 11, 2017
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 6.49
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 6.37
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet (2000) 6.12
Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res (2002) 5.93
A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science (2010) 5.84
Tbr1 regulates differentiation of the preplate and layer 6. Neuron (2001) 5.19
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med (2004) 4.63
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
Loss of Nkx2.1 homeobox gene function results in a ventral to dorsal molecular respecification within the basal telencephalon: evidence for a transformation of the pallidum into the striatum. Development (1999) 4.26
Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet (1995) 3.72
A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol (2006) 3.46
Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev (2003) 3.46
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 3.45
Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol (2010) 3.37
Gene silencing using micro-RNA designed hairpins. RNA (2002) 3.21
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A (2007) 3.07
Characterization of Foxp2 and Foxp1 mRNA and protein in the developing and mature brain. J Comp Neurol (2003) 3.01
Inactivation of the mouse Huntington's disease gene homolog Hdh. Science (1995) 2.96
An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun (2004) 2.84
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
The determination of projection neuron identity in the developing cerebral cortex. Curr Opin Neurobiol (2008) 2.77
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A (2010) 2.67
Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther (2008) 2.66
The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res (2003) 2.64
Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron (2010) 2.54
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. Proc Natl Acad Sci U S A (2010) 2.45
Vesicular glycolysis provides on-board energy for fast axonal transport. Cell (2013) 2.33
siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res (2004) 2.30
In situ detection and genotyping of individual mRNA molecules. Nat Methods (2010) 2.29
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem (2003) 2.29
Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol (2009) 2.05
Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J (2008) 2.03
Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther (2006) 1.99
Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J Neurosci (2008) 1.97
Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci (2000) 1.92
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
Tbr1 and Fezf2 regulate alternate corticofugal neuronal identities during neocortical development. J Neurosci (2011) 1.81
Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther (2000) 1.81
NKX2.1 specifies cortical interneuron fate by activating Lhx6. Development (2008) 1.79
Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res (2005) 1.68
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci (2005) 1.68
TBR1 directly represses Fezf2 to control the laminar origin and development of the corticospinal tract. Proc Natl Acad Sci U S A (2011) 1.67
Overcoming the innate immune response to small interfering RNA. Hum Gene Ther (2008) 1.64
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol (2009) 1.59
Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res (1998) 1.54
Local RNA target structure influences siRNA efficacy: a systematic global analysis. J Mol Biol (2005) 1.54
The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci (2006) 1.52
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain (2012) 1.49
Defining the optimal parameters for hairpin-based knockdown constructs. RNA (2007) 1.48
Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation (2004) 1.45
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun (2006) 1.45
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther (2008) 1.44
Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci (2002) 1.40
A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet (2011) 1.39
Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci (2010) 1.33
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther (2008) 1.31
A set of highly conserved RNA-binding proteins, alphaCP-1 and alphaCP-2, implicated in mRNA stabilization, are coexpressed from an intronless gene and its intron-containing paralog. J Biol Chem (1999) 1.26
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther (2011) 1.22
Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci (2000) 1.21
mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol (2010) 1.21
siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics (2009) 1.20
Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA (2009) 1.16
Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. Nat Struct Mol Biol (2011) 1.16
Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res (2004) 1.10
Foxp1 gene expression in projection neurons of the mouse striatum. Neuroscience (2004) 1.09
Functional parameters of Dicer-independent microRNA biogenesis. RNA (2012) 1.08
Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing. Nucleic Acids Res (2012) 1.07
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA. Oligonucleotides (2007) 1.05
The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence (2011) 1.00
The effects of stem length and core placement on shRNA activity. BMC Mol Biol (2011) 1.00
The Huntington's Disease health-related Quality of Life questionnaire (HDQoL): a disease-specific measure of health-related quality of life. Clin Genet (2012) 0.98
Designing Ago2-specific siRNA/shRNA to Avoid Competition with Endogenous miRNAs. Mol Ther Nucleic Acids (2014) 0.97
High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther (2007) 0.97
Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database. BMC Neurol (2012) 0.96
Modeling RNA interference in mammalian cells. BMC Syst Biol (2011) 0.96
Update on Huntington's disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord (2014) 0.96
Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development (2015) 0.95
Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther (2007) 0.94
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res (2012) 0.93
The Biology of Huntingtin. Neuron (2016) 0.91
The mouse cortico-striatal projectome. Nat Neurosci (2016) 0.89
Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem Biophys Res Commun (2005) 0.89
Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument. Int Clin Psychopharmacol (2012) 0.89
Embryonic stem cells neural differentiation qualifies the role of Wnt/β-Catenin signals in human telencephalic specification and regionalization. Stem Cells (2013) 0.88
Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A (2016) 0.88
Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9. Hum Mol Genet (2016) 0.86
Measurement of lentiviral vector titre and copy number by cross-species duplex quantitative PCR. Gene Ther (2015) 0.85